Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 41

Related Articles by Review for PubMed (Select 20584808)

1.

A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB.

Oncologist. 2010;15(7):699-731. doi: 10.1634/theoncologist.2010-0025. Epub 2010 Jun 28. Review.

2.

Clinical biomarkers in oncology: focus on colorectal cancer.

De Roock W, Biesmans B, De Schutter J, Tejpar S.

Mol Diagn Ther. 2009;13(2):103-14. doi: 10.2165/01250444-200913020-00004. Review.

PMID:
19537845
3.

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.

Custodio A, Feliu J.

Crit Rev Oncol Hematol. 2013 Jan;85(1):45-81. doi: 10.1016/j.critrevonc.2012.05.001. Epub 2012 May 28. Review.

PMID:
22647972
4.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

5.

Predictive molecular classifiers in colorectal cancer.

Bohanes P, LaBonte MJ, Winder T, Lenz HJ.

Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Review.

PMID:
21810517
6.

Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach.

Legolvan MP, Taliano RJ, Resnick MB.

Hum Pathol. 2012 Aug;43(8):1157-68. doi: 10.1016/j.humpath.2012.03.003. Epub 2012 Jun 1. Review.

PMID:
22658275
7.

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Review.

PMID:
21129611
8.

Molecular markers in the treatment of metastatic colorectal cancer.

Wilson PM, Labonte MJ, Lenz HJ.

Cancer J. 2010 May-Jun;16(3):262-72. doi: 10.1097/PPO.0b013e3181e07738. Review.

PMID:
20526105
9.

Development of molecular biomarkers in individualized treatment of colorectal cancer.

De Mattos-Arruda L, Dienstmann R, Tabernero J.

Clin Colorectal Cancer. 2011 Dec;10(4):279-89. doi: 10.1016/j.clcc.2011.03.030. Epub 2011 May 12. Review.

PMID:
21729679
10.

Personalizing therapy for colorectal cancer.

Wong A, Ma BB.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):139-44. doi: 10.1016/j.cgh.2013.08.040. Epub 2013 Sep 8. Review.

PMID:
24025538
11.

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].

Fabian P, Berkovcová J.

Cesk Patol. 2011 Oct;47(4):154-8. Review. Czech.

PMID:
22145213
12.
13.

Molecular predictors of response to chemotherapy in colorectal cancer.

Dienstmann R, Vilar E, Tabernero J.

Cancer J. 2011 Mar-Apr;17(2):114-26. doi: 10.1097/PPO.0b013e318212f844. Review.

PMID:
21427555
14.

A review on biomarkers for prediction of treatment outcome in gastric cancer.

Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M.

Anticancer Res. 2013 Apr;33(4):1257-66. Review.

PMID:
23564763
15.

Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.

Barton S, Starling N, Swanton C.

Curr Cancer Drug Targets. 2010 Dec;10(8):799-812. Review.

PMID:
20718710
16.

Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist.

Søreide K, Nedrebø BS, Knapp JC, Glomsaker TB, Søreide JA, Kørner H.

Surg Oncol. 2009 Mar;18(1):31-50. doi: 10.1016/j.suronc.2008.06.006. Epub 2008 Jul 30. Review.

PMID:
18672360
17.

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S.

Target Oncol. 2010 Mar;5(1):19-28. doi: 10.1007/s11523-010-0138-5. Epub 2010 Apr 11. Review. Erratum in: Target Oncol. 2012 Dec;7(4):267.

PMID:
20383783
18.
19.

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.

Tímár J, Hegedüs B, Rásó E.

Curr Cancer Drug Targets. 2010 Dec;10(8):813-23. Review.

PMID:
20718705
20.

Implementing prognostic and predictive biomarkers in CRC clinical trials.

Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG.

Nat Rev Clin Oncol. 2011 Feb 15;8(4):222-32. doi: 10.1038/nrclinonc.2011.15. Review.

PMID:
21321566
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk